Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportRadiopharmaceutical Chemistry: New Radiopharmaceuticals

68Ga-glucosamine analogs for PET imaging of cancer

Izabela Tworowska, Hitomi Saso, Jennifer Sims-Mourtada, Firas Mourtada, Ebrahim Delpassand and Ali Azhdarinia
Journal of Nuclear Medicine May 2009, 50 (supplement 2) 376;
Izabela Tworowska
1RITA Foundation, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hitomi Saso
2RadioMedix, Inc., Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Sims-Mourtada
2RadioMedix, Inc., Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Firas Mourtada
3The University of Texas M.D. Anderson Cancer Center, Dept. of Expt. Diagnostic Imaging, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ebrahim Delpassand
2RadioMedix, Inc., Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ali Azhdarinia
2RadioMedix, Inc., Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

376

Objectives 68Ga-PET provides a cost-effective alternative to cyclotron produced PET agents, but is limited by the number of functional agents available. This study reports on development of 68Ga-based glucosamine derivatives as new PET agents for cancer imaging.

Methods A small library of tetraazacyclododecane-glucosamine derivatives were prepared by coupling glucosamine to functional groups present on the chelators (i.e. methylene carboxy groups of DOTA). Reactions were performed in the presence of peptide coupling agents and purified by crystallization, extraction and subsequent precipitation. The compound was labeled with 68Ga in acetate buffer and heated at 95oC for 10-20 min. Radiochemical yield and purity were assessed. In vitro bioactivity was evaluated by cellular uptake studies and hexokinase (Hx) assay. MicroPET images were obtained using breast and colon tumor bearing models.

Results Multiple tetraazacyclododecane-glucosamine derivatives were synthesized with 50-60% yield, and structures were confirmed by NMR and mass spectrometry. Radiochemical yield was dependent on conjugation scheme, and was >95% for lead compounds. Cellular uptake studies showed increased accumulation in cancer cells as a function of time. The rates of phosphorylation by Hx were comparable for lead compounds, FDG and free glucosamine. Tumor localization was observed in animal models using micro PET.

Conclusions An efficient synthesis strategy was developed for 68Ga-glucosamine conjugates. Preliminary studies show promise that 68Ga-labeled glucosamine derivatives may be a broad-use, low-cost alternative for PET imaging of tumors.

  • © 2009 by Society of Nuclear Medicine
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 50, Issue supplement 2
May 2009
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
68Ga-glucosamine analogs for PET imaging of cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
68Ga-glucosamine analogs for PET imaging of cancer
Izabela Tworowska, Hitomi Saso, Jennifer Sims-Mourtada, Firas Mourtada, Ebrahim Delpassand, Ali Azhdarinia
Journal of Nuclear Medicine May 2009, 50 (supplement 2) 376;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
68Ga-glucosamine analogs for PET imaging of cancer
Izabela Tworowska, Hitomi Saso, Jennifer Sims-Mourtada, Firas Mourtada, Ebrahim Delpassand, Ali Azhdarinia
Journal of Nuclear Medicine May 2009, 50 (supplement 2) 376;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Radiopharmaceutical Chemistry: New Radiopharmaceuticals

  • Preparation of a novel bifunctional chelator AmBaSar based on sarcophagine for Cu-64 radiopharmaceuticals
  • Development of 68Ga-lactosylated human serum albumin (LSA) for imaging the hepatic asialoglycoprotein receptor
  • Pre-clinical evaluation of 124I-FIAU and 18F-FIAU for the assessment of the HSV1-tk reporter gene expression with PET
Show more Radiopharmaceutical Chemistry: New Radiopharmaceuticals

Novel Probe Development III

  • Identification of the optimal Cu-64 bifunctional chelator for radioimmunodetection of neuroblastoma
  • Evaluation of 64Cu-DOTA-KCCYSL and 64Cu-CB-TE2A-KCCYSL peptides as PET imaging agents for ErbB-2 expressing breast carcinomas
Show more Novel Probe Development III

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire